GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Yew Bio-Pharm Group Inc (OTCPK:YEWB) » Definitions » Beneish M-Score

Yew Bio-Pharm Group (Yew Bio-Pharm Group) Beneish M-Score : 0.00 (As of May. 08, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Yew Bio-Pharm Group Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Yew Bio-Pharm Group's Beneish M-Score or its related term are showing as below:

During the past 10 years, the highest Beneish M-Score of Yew Bio-Pharm Group was 0.00. The lowest was 0.00. And the median was 0.00.


Yew Bio-Pharm Group Beneish M-Score Historical Data

The historical data trend for Yew Bio-Pharm Group's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yew Bio-Pharm Group Beneish M-Score Chart

Yew Bio-Pharm Group Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.35 -1.45 -5.47 1.85 -3.91

Yew Bio-Pharm Group Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.66 -3.91 -3.30 -2.07 4.84

Competitive Comparison of Yew Bio-Pharm Group's Beneish M-Score

For the Farm Products subindustry, Yew Bio-Pharm Group's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yew Bio-Pharm Group's Beneish M-Score Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Yew Bio-Pharm Group's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Yew Bio-Pharm Group's Beneish M-Score falls into.



Yew Bio-Pharm Group Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Yew Bio-Pharm Group for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2317+0.528 * 16.0791+0.404 * 1.0189+0.892 * 1.1582+0.115 * 0.9648
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6555+4.679 * -0.217665-0.327 * 1.1246
=4.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep21) TTM:Last Year (Sep20) TTM:
Total Receivables was $13.78 Mil.
Revenue was 0.11 + 14.844 + 8.737 + 5.361 = $29.05 Mil.
Gross Profit was -0.84 + -0.228 + 0.957 + 0.274 = $0.16 Mil.
Total Current Assets was $13.93 Mil.
Total Assets was $61.40 Mil.
Property, Plant and Equipment(Net PPE) was $0.83 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.82 Mil.
Selling, General, & Admin. Expense(SGA) was $0.96 Mil.
Total Current Liabilities was $12.54 Mil.
Long-Term Debt & Capital Lease Obligation was $0.24 Mil.
Net Income was -1.55 + -0.545 + 2.918 + -0.42 = $0.40 Mil.
Non Operating Income was -0.374 + 0.026 + 2.357 + -0.303 = $1.71 Mil.
Cash Flow from Operations was 5.895 + 1.813 + -0.776 + 5.129 = $12.06 Mil.
Total Receivables was $9.66 Mil.
Revenue was 10.355 + 9.562 + 2.029 + 3.137 = $25.08 Mil.
Gross Profit was 1.525 + 1.285 + 0.442 + -0.989 = $2.26 Mil.
Total Current Assets was $13.60 Mil.
Total Assets was $56.67 Mil.
Property, Plant and Equipment(Net PPE) was $0.82 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.42 Mil.
Selling, General, & Admin. Expense(SGA) was $1.27 Mil.
Total Current Liabilities was $10.20 Mil.
Long-Term Debt & Capital Lease Obligation was $0.30 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(13.782 / 29.052) / (9.661 / 25.083)
=0.474391 / 0.385161
=1.2317

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.263 / 25.083) / (0.163 / 29.052)
=0.09022 / 0.005611
=16.0791

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (13.934 + 0.827) / 61.397) / (1 - (13.597 + 0.824) / 56.666)
=0.759581 / 0.745509
=1.0189

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=29.052 / 25.083
=1.1582

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.418 / (2.418 + 0.824)) / (2.817 / (2.817 + 0.827))
=0.745836 / 0.773052
=0.9648

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0.962 / 29.052) / (1.267 / 25.083)
=0.033113 / 0.050512
=0.6555

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.242 + 12.544) / 61.397) / ((0.295 + 10.198) / 56.666)
=0.208251 / 0.185173
=1.1246

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(0.403 - 1.706 - 12.061) / 61.397
=-0.217665

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Yew Bio-Pharm Group has a M-score of 4.84 signals that the company is likely to be a manipulator.


Yew Bio-Pharm Group Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Yew Bio-Pharm Group's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Yew Bio-Pharm Group (Yew Bio-Pharm Group) Business Description

Traded in Other Exchanges
N/A
Address
9460 Telstar Avenue, Suite 6, El Monte, CA, USA, 91731
Yew Bio-Pharm Group Inc is a grower and seller of yew trees and manufacturer of products made from yew trees in China. The company also sells raw material, including the branches and leaves of yew trees, used in the manufacturing of traditional Chinese medicines, which are used as a secondary treatment for certain cancers, meaning they must be administered in combination with other pharmaceutical drugs. The company operating business segments are China and the United States, of which the majority of its revenue comes from China.
Executives
Yongchun Shi director 9460 TELSTAR AVENUE, SUITE 6 EL MONTE CA 91302
Xiefeng Liu director 9460 TELSTAR AVENUE, SUITE 6 EL MONTE CA 91731
Guoshuang Tian director 9460 TELSTAR AVENUE, SUITE 6 EL MONTE CA 91731
Xuehai Wu director 9460 TELSTAR AVENUE, SUITE 6 EL MONTE CA 91731
Xingming Han director DOOR 3, FLOOR 7, VIC NO.23 TONGZHAN ST. XIANGFANG DISTRICT HARBIN CITY F4 XXXXXXXXX
Adam C Wasserman officer: Chief Financial Officer 1643 ROYAL GROVE WAY, WESTON FL 33327
Guifang Qi director, officer: Treasurer 501 N. MOORE AVE. APT. A MONTEREY PARK CA 91754
Zhiguo Wang director, officer: President and Secretary NO. 234, GEXIN STREET NANGANG DISTRICT HARBIN CITY F4 XXXXXXXXX

Yew Bio-Pharm Group (Yew Bio-Pharm Group) Headlines

From GuruFocus

Yew Bio-Pharm Group Announces New Cosmetic Subsidiary

By Marketwired Marketwired 03-09-2021

Yew Bio-Pharm Group Announces New Significant Agreement

By Marketwired Marketwired 09-12-2018